• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫组化染色在原发性中枢神经系统淋巴瘤中的诊断应用

Immune landscape of oncohistone-mutant gliomas reveals diverse myeloid populations and tumor-promoting function.

机构信息

Department of Human Genetics, McGill University, Montreal, QC, H3A 0C7, Canada.

The Research Institute of the McGill University Health Centre, Montreal, QC, H4A 3J1, Canada.

出版信息

Nat Commun. 2024 Sep 5;15(1):7769. doi: 10.1038/s41467-024-52096-w.

DOI:10.1038/s41467-024-52096-w
PMID:39237515
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11377583/
Abstract

Histone H3-mutant gliomas are deadly brain tumors characterized by a dysregulated epigenome and stalled differentiation. In contrast to the extensive datasets available on tumor cells, limited information exists on their tumor microenvironment (TME), particularly the immune infiltrate. Here, we characterize the immune TME of H3.3K27M and G34R/V-mutant gliomas, and multiple H3.3K27M mouse models, using transcriptomic, proteomic and spatial single-cell approaches. Resolution of immune lineages indicates high infiltration of H3-mutant gliomas with diverse myeloid populations, high-level expression of immune checkpoint markers, and scarce lymphoid cells, findings uniformly reproduced in all H3.3K27M mouse models tested. We show these myeloid populations communicate with H3-mutant cells, mediating immunosuppression and sustaining tumor formation and maintenance. Dual inhibition of myeloid cells and immune checkpoint pathways show significant therapeutic benefits in pre-clinical syngeneic mouse models. Our findings provide a valuable characterization of the TME of oncohistone-mutant gliomas, and insight into the means for modulating the myeloid infiltrate for the benefit of patients.

摘要

组蛋白 H3 突变型神经胶质瘤是致命的脑肿瘤,其特征是表观基因组失调和分化停滞。与肿瘤细胞的大量数据集相比,关于其肿瘤微环境(TME)的信息有限,特别是免疫浸润。在这里,我们使用转录组学、蛋白质组学和空间单细胞方法来描述 H3.3K27M 和 G34R/V 突变型神经胶质瘤以及多种 H3.3K27M 小鼠模型的免疫 TME。免疫谱系的解析表明,H3 突变型神经胶质瘤高度浸润具有多种髓系群体,高水平表达免疫检查点标志物,以及稀少的淋巴样细胞,这些发现均在所有测试的 H3.3K27M 小鼠模型中得到了一致的重现。我们表明这些髓系群体与 H3 突变细胞相互作用,介导免疫抑制并维持肿瘤的形成和维持。在同种异体小鼠模型中,髓样细胞和免疫检查点途径的双重抑制显示出显著的治疗益处。我们的研究结果为癌组蛋白突变型神经胶质瘤的 TME 提供了有价值的描述,并深入了解了调节髓样浸润以造福患者的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17af/11377583/6f9151ceefd1/41467_2024_52096_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17af/11377583/4cad4e6fd38e/41467_2024_52096_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17af/11377583/2fc029fd51a9/41467_2024_52096_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17af/11377583/6102dcd76b72/41467_2024_52096_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17af/11377583/f06c3f5943f9/41467_2024_52096_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17af/11377583/bc138455dc0d/41467_2024_52096_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17af/11377583/6f9151ceefd1/41467_2024_52096_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17af/11377583/4cad4e6fd38e/41467_2024_52096_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17af/11377583/2fc029fd51a9/41467_2024_52096_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17af/11377583/6102dcd76b72/41467_2024_52096_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17af/11377583/f06c3f5943f9/41467_2024_52096_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17af/11377583/bc138455dc0d/41467_2024_52096_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17af/11377583/6f9151ceefd1/41467_2024_52096_Fig6_HTML.jpg

相似文献

1
Immune landscape of oncohistone-mutant gliomas reveals diverse myeloid populations and tumor-promoting function.免疫组化染色在原发性中枢神经系统淋巴瘤中的诊断应用
Nat Commun. 2024 Sep 5;15(1):7769. doi: 10.1038/s41467-024-52096-w.
2
Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma.突变 IDH 调节恶性神经胶质瘤中的抑制性髓系群体。
Clin Cancer Res. 2024 Sep 13;30(18):4068-4076. doi: 10.1158/1078-0432.CCR-24-1056.
3
Characteristics and outcomes of diffuse non-midline gliomas with H3F3A gene mutation in the Kansai Molecular Diagnosis Network for CNS Tumors (Kansai Network): multicenter retrospective cohort study.关西中枢神经系统肿瘤分子诊断网络(关西网络)中伴有H3F3A基因突变的弥漫性非中线胶质瘤的特征与预后:多中心回顾性队列研究
Acta Neuropathol Commun. 2025 Apr 16;13(1):77. doi: 10.1186/s40478-025-01989-y.
4
Systematic Analysis of an Immune-Related Gene Signature for Predicting Prognosis and Immune Characteristics in Primary Lower Grade Glioma.用于预测原发性低级别胶质瘤预后和免疫特征的免疫相关基因特征的系统分析
Biomed Res Int. 2025 Aug 12;2025:6180391. doi: 10.1155/bmri/6180391. eCollection 2025.
5
Comprehensive immune ageing reveals TREM2/TIM3 myeloid cells drive brain immune evasion.全面的免疫衰老揭示TREM2/TIM3髓样细胞驱动脑部免疫逃逸。
EBioMedicine. 2025 Jun 27;118:105833. doi: 10.1016/j.ebiom.2025.105833.
6
Identification of an immunomodulatory lncRNA signature associated with immune cell reprogramming in high-grade glioma.在高级别胶质瘤中鉴定与免疫细胞重编程相关的免疫调节性长链非编码RNA特征。
Cancer Gene Ther. 2025 Jun 17. doi: 10.1038/s41417-025-00919-3.
7
Interplay between tumor mutation burden and the tumor microenvironment predicts the prognosis of pan-cancer anti-PD-1/PD-L1 therapy.肿瘤突变负荷与肿瘤微环境之间的相互作用可预测泛癌抗PD-1/PD-L1治疗的预后。
Front Immunol. 2025 Jul 24;16:1557461. doi: 10.3389/fimmu.2025.1557461. eCollection 2025.
8
Integrated Transcriptome Profiling and Pan-Cancer Analyses Reveal Oncogenic Networks and Tumor-Immune Modulatory Roles for FABP7 in Brain Cancers.整合转录组谱分析和泛癌分析揭示 FABP7 在脑肿瘤中的致癌网络和肿瘤免疫调节作用。
Int J Mol Sci. 2024 Nov 14;25(22):12231. doi: 10.3390/ijms252212231.
9
High-resolution transcriptome atlas of bladder cancer highlights the functional myeloid subsets in modulating immune microenvironment.膀胱癌的高分辨率转录组图谱揭示了调节免疫微环境的功能性髓系亚群。
EBioMedicine. 2025 Jul;117:105801. doi: 10.1016/j.ebiom.2025.105801. Epub 2025 Jun 24.
10
A multi-cohort validated OXPHOS signature predicts survival and immune profiles in grade II/III glioma patients.一种经过多队列验证的氧化磷酸化特征可预测II/III级胶质瘤患者的生存率和免疫特征。
Front Immunol. 2025 Aug 1;16:1638824. doi: 10.3389/fimmu.2025.1638824. eCollection 2025.

引用本文的文献

1
A spatial map of MAPK-activated immunosuppressive myeloid populations in pediatric low-grade glioma.小儿低级别胶质瘤中MAPK激活的免疫抑制性髓系细胞群的空间图谱。
Nat Immunol. 2025 Sep 15. doi: 10.1038/s41590-025-02268-7.
2
Current Landscape of Preclinical Models for Pediatric Gliomas: Clinical Implications and Future Directions.小儿胶质瘤临床前模型的现状:临床意义与未来方向
Cancers (Basel). 2025 Jul 2;17(13):2221. doi: 10.3390/cancers17132221.
3
Defining the extracellular matrix for targeted immunotherapy in adult and pediatric brain cancer.

本文引用的文献

1
Tumor and immune cell types interact to produce heterogeneous phenotypes of pediatric high-grade glioma.肿瘤细胞和免疫细胞相互作用产生异质性表型的小儿高级别胶质瘤。
Neuro Oncol. 2024 Mar 4;26(3):538-552. doi: 10.1093/neuonc/noad207.
2
A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities.《同基因、可移植儿科高级别神经胶质瘤模型概述揭示了亚型特异性治疗弱点》。
Cancer Discov. 2023 Jul 7;13(7):1592-1615. doi: 10.1158/2159-8290.CD-23-0004.
3
Single substitution in H3.3G34 alters DNMT3A recruitment to cause progressive neurodegeneration.
定义用于成人和儿童脑癌靶向免疫治疗的细胞外基质。
NPJ Precis Oncol. 2025 Jun 14;9(1):184. doi: 10.1038/s41698-025-00956-z.
4
Exploring the tumor microenvironment in diffuse intrinsic pontine glioma: immunological insights and therapeutic challenges.探索弥漫性脑桥内在型胶质瘤的肿瘤微环境:免疫学见解与治疗挑战
J Immunother Cancer. 2025 Jun 12;13(6):e012009. doi: 10.1136/jitc-2025-012009.
5
Therapeutic approaches for targeting the pediatric brain tumor microenvironment.针对小儿脑肿瘤微环境的治疗方法。
Drug Deliv Transl Res. 2025 Apr 21. doi: 10.1007/s13346-025-01839-3.
6
Microenvironmental Drivers of Glioma Progression.胶质瘤进展的微环境驱动因素
Int J Mol Sci. 2025 Feb 27;26(5):2108. doi: 10.3390/ijms26052108.
7
A scoping review of diffuse hemispheric glioma, H3 G34-mutant: Epigenetic and molecular profiles, clinicopathology, and treatment avenues.弥漫性半球胶质瘤H3 G34突变型的范围综述:表观遗传学和分子特征、临床病理学及治疗途径
Neurooncol Adv. 2024 Dec 7;6(1):vdae208. doi: 10.1093/noajnl/vdae208. eCollection 2024 Jan-Dec.
8
Neuroimmune-competent human brain organoid model of diffuse midline glioma.弥漫性中线胶质瘤的神经免疫活性人脑类器官模型
Neuro Oncol. 2025 Feb 10;27(2):369-382. doi: 10.1093/neuonc/noae245.
H3.3G34 单点替换导致 DNMT3A 募集改变从而引发进行性神经退行性变。
Cell. 2023 Mar 16;186(6):1162-1178.e20. doi: 10.1016/j.cell.2023.02.023.
4
Single-cell spatial immune landscapes of primary and metastatic brain tumours.原发性和转移性脑肿瘤的单细胞空间免疫图谱。
Nature. 2023 Feb;614(7948):555-563. doi: 10.1038/s41586-022-05680-3. Epub 2023 Feb 1.
5
K27M in canonical and noncanonical H3 variants occurs in distinct oligodendroglial cell lineages in brain midline gliomas.K27M 在经典和非经典 H3 变体中发生在脑中线胶质瘤中不同的少突胶质细胞谱系中。
Nat Genet. 2022 Dec;54(12):1865-1880. doi: 10.1038/s41588-022-01205-w. Epub 2022 Dec 5.
6
The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location.H3-K27M 突变弥漫性中线胶质瘤在年龄和位置上的肿瘤细胞状态和空间组织景观。
Nat Genet. 2022 Dec;54(12):1881-1894. doi: 10.1038/s41588-022-01236-3. Epub 2022 Dec 5.
7
Proposed practical protocol for flow cytometry analysis of microglia from the healthy adult mouse brain: Systematic review and isolation methods' evaluation.健康成年小鼠大脑小胶质细胞流式细胞术分析的拟行实用方案:系统评价与分离方法评估
Front Cell Neurosci. 2022 Oct 19;16:1017976. doi: 10.3389/fncel.2022.1017976. eCollection 2022.
8
A common framework of monocyte-derived macrophage activation.单核细胞衍生的巨噬细胞激活的通用框架。
Sci Immunol. 2022 Apr 15;7(70):eabl7482. doi: 10.1126/sciimmunol.abl7482.
9
Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome.MAT2A 的缺失会影响蛋氨酸代谢,并通过调节表观基因组在 H3K27M 突变型神经胶质瘤中表现出脆弱性。
Nat Cancer. 2022 May;3(5):629-648. doi: 10.1038/s43018-022-00348-3. Epub 2022 Apr 14.
10
The current landscape of immunotherapy for pediatric brain tumors.儿童脑肿瘤免疫治疗的现状。
Nat Cancer. 2022 Jan;3(1):11-24. doi: 10.1038/s43018-021-00319-0. Epub 2022 Jan 20.